CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype von Helsby, N A, Lo, W-Y, Sharples, K, Riley, G, Murray, M, Spells, K, Dzhelai, M, Simpson, A, Findlay, M

Volltext

CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity von Burns, K. E., Goldthorpe, M. A., Porteus, F., Browett, P., Helsby, N. A.

Volltext

Comparative bioactivation of the novel anti‐tuberculosis agent PA‐824 in Mycobacteria and a subcellular fraction of human liver von Dogra, M, Palmer, BD, Bashiri, G, Tingle, MD, Shinde, SS, Anderson, RF, O'Toole, R, Baker, EN, Denny, WA, Helsby, NA

Volltext

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes von Helsby, N.A., Yong, M., Kan, M., Zoysa, J.R., Burns, K.E.

Volltext

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT von HELSBY, N. A, FERRY, D. M, PATTERSON, A. V, PULLEN, S. M, WILSON, W. R

Volltext

Do 5-fluorouracil therapies alter CYP2C19 metaboliser status von Helsby, N. A, Lo, W. Y, Thompson, P, Laking, G. R

Volltext

Can in vitro drug metabolism studies with human tissue replace in vivo animal studies? von Tingle, M.D., Helsby, N.A.

Volltext

High CYP2C19 phenotypic variability in gastrointestinal cancer patients von Burns, K. E., Lo, W.-Y., Findlay, M. P., Sharples, K., Laking, G., Helsby, N. A.

Volltext

Inhibition of Mouse and Human CYP 1A- and 2E1-dependent Substrate Metabolism by the Isoflavonoids Genistein and Equol von Helsby, N.A, Chipman, J.K, Gescher, A, Kerr, D

Volltext

The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents von Bull, M. R., Spicer, J. A., Huttunen, K. M., Denny, W. A., Ciccone, A., Browne, K. A., Trapani, J. A., Helsby, N. A.

Volltext

isoflavones equol and genistein do not induce xenobiotic-metabolizing enzymes in mouse and in human cells von HELSBY, N. A., WILLIAMS, J., KERR, D., GESCHER, A., CHIPMAN, J. K.

Volltext

Interleukin-4 differentially regulates prostaglandin production in amnion-derived WISH cells stimulated with pro-inflammatory cytokines and epidermal growth factor von Keelan, J.A., Sato, T.A., Hansen, W.R., Gilmour, J.S., Gupta, D.K., Helsby, N.A., Mitchell, M.D.

Volltext

The role of S‐mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides von Wright, JD, Helsby, NA, Ward, SA

Volltext

The multiple dose pharmacokinetics of proguanil von Helsby, NA, Edwards, G, Breckenridge, AM, Ward, SA

Volltext

The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism von Helsby, NA, Ward, SA, Edwards, G, Howells, RE, Breckenridge, AM

Volltext

Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety von Tucci, Joseph D, Pumuye, Paul P, Helsby, Nuala A, Barratt, Daniel T, Pokeya, Percy P, Hombhanje, Francis, Somogyi, Andrew A

Volltext

The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism‐a panel study von Ward, SA, Helsby, NA, Skjelbo, E., Brosen, K., Gram, LF, Breckenridge, AM

Volltext

Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards von Wilson, William R., Hicks, Kevin O., Pullen, Susan M., Ferry, Dianne M., Helsby, Nuala A., Patterson, Adam V.

Volltext

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme von Helsby, NA, Ward, SA, Howells, RE, Breckenridge, AM

Volltext

Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound von Helsby, N A, Ward, S A, Parslew, R A, Friedmann, P S, Rhodes, L E

Volltext